Aberrant JAK activation in human tumorigenesis was originally confirmed by the identification of the ETV6-JAK2 (t(9;12) translocation breakpoint, previously known as TEL-JAK2 fusion protein in ALL and CML patients [49,50]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.